205 related articles for article (PubMed ID: 15999996)
1. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
Hancock CN; Macias A; Lee EK; Yu SY; Mackerell AD; Shapiro P
J Med Chem; 2005 Jul; 48(14):4586-95. PubMed ID: 15999996
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure.
Chen F; Hancock CN; Macias AT; Joh J; Still K; Zhong S; MacKerell AD; Shapiro P
Bioorg Med Chem Lett; 2006 Dec; 16(24):6281-7. PubMed ID: 17000106
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.
Eblen ST; Catling AD; Assanah MC; Weber MJ
Mol Cell Biol; 2001 Jan; 21(1):249-59. PubMed ID: 11113199
[TBL] [Abstract][Full Text] [Related]
4. Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.
Boston SR; Deshmukh R; Strome S; Priyakumar UD; MacKerell AD; Shapiro P
BMC Cancer; 2011 Jan; 11():7. PubMed ID: 21219631
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity.
Burkhard KA; Chen F; Shapiro P
J Biol Chem; 2011 Jan; 286(4):2477-85. PubMed ID: 21098038
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
[TBL] [Abstract][Full Text] [Related]
7. Identifying specific kinase substrates through engineered kinases and ATP analogs.
Kumar NV; Eblen ST; Weber MJ
Methods; 2004 Apr; 32(4):389-97. PubMed ID: 15003601
[TBL] [Abstract][Full Text] [Related]
8. A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.
Sammons RM; Perry NA; Li Y; Cho EJ; Piserchio A; Zamora-Olivares DP; Ghose R; Kaoud TS; Debevec G; Bartholomeusz C; Gurevich VV; Iverson TM; Giulianotti M; Houghten RA; Dalby KN
ACS Chem Biol; 2019 Jun; 14(6):1183-1194. PubMed ID: 31058487
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration.
Yang S; Ji M; Zhang L; Chen Y; Wennmann DO; Kremerskothen J; Dong J
Cell Signal; 2014 Feb; 26(2):343-51. PubMed ID: 24269383
[TBL] [Abstract][Full Text] [Related]
10. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
Mut M; Lule S; Demir O; Kurnaz IA; Vural I
Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.
Samadani R; Zhang J; Brophy A; Oashi T; Priyakumar UD; Raman EP; St John FJ; Jung KY; Fletcher S; Pozharski E; MacKerell AD; Shapiro P
Biochem J; 2015 May; 467(3):425-38. PubMed ID: 25695333
[TBL] [Abstract][Full Text] [Related]
12. Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo.
Dimitri CA; Dowdle W; MacKeigan JP; Blenis J; Murphy LO
Curr Biol; 2005 Jul; 15(14):1319-24. PubMed ID: 16051177
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of RSK2 and Elk-1 interaction on the serum response element and implications for cellular engineering.
Aksan Kurnaz I
Biotechnol Bioeng; 2004 Dec; 88(7):890-900. PubMed ID: 15515167
[TBL] [Abstract][Full Text] [Related]
14. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
15. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication.
Andrade AA; Silva PN; Pereira AC; De Sousa LP; Ferreira PC; Gazzinelli RT; Kroon EG; Ropert C; Bonjardim CA
Biochem J; 2004 Jul; 381(Pt 2):437-46. PubMed ID: 15025565
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during contextual fear conditioning: interactions between Erk-1/2 and Elk-1.
Sananbenesi F; Fischer A; Schrick C; Spiess J; Radulovic J
Mol Cell Neurosci; 2002 Nov; 21(3):463-76. PubMed ID: 12498787
[TBL] [Abstract][Full Text] [Related]
17. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA
Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800
[TBL] [Abstract][Full Text] [Related]
19. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
[TBL] [Abstract][Full Text] [Related]
20. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
